CytoReason and Pfizer ink $110 million AI deal

Extending a previous accord with the US pharma giant, Israel-based CytoReason has now signed a new partnership with Pfizer (NYSE: PFE) to use CytoReason’s artificial intelligence technology for Pfizer’s drug development programs for a further five years.

Under the terms of the new deal, Pfizer will make a $20 million equity investment, have options to license CytoReason’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110 million over the next five years.

Since launching the collaboration in 2019, Pfizer has used CytoReason's biological models in its research to enhance the understanding of the immune system, as it develops innovative drugs for immune-mediated and immuno-oncology diseases. CytoReason's platform has provided Pfizer with multiple insights in research and development programs across over 20 diseases.